-
Why Johnson & Johnson's Strong Pharmaceutical Business Is A Concern
Tuesday, April 14, 2015 - 2:45pm | 392Read More...Johnson & Johnson (NYSE: JNJ) came out with better-than-expected earnings on Tuesday, despite the strong headwind it faced from the rising dollar. The company reported first-quarter EPS of $1.56, compared to $1.54 in the same quarter last year, while revenue dropped to $17.4 billion, from $18...
-
Ryan Recommends Bristol-Myers and Merck (BMY, MRK, PFE)
Wednesday, July 14, 2010 - 4:48pm | 134Read More...Barbara Ryan, senior pharmaceuticals analyst with Deutsche Bank, is optimistic about pharma companies. In an interview with CNBC, she said, “The focus is on those companies today that have the right strategies, are addressing the challenges on their top line with radical restructuring of the cost...
